Evaluation of a pharmacist-managed diabetes medication therapy adherence clinic

Main Article Content

Phei C. Lim
Kelvin Lim


Diabetes, Medication Adherence, Pharmacists, Malaysia


Patient adherence to prescribed medication regimens is important in diabetes care to prevent or delay microvascular and macrovascular complications such as retinopathy, nephropathy and myocardial infarction. In Penang Hospital, Malaysia, pharmacists collaborate with physicians in diabetes care through a pharmacist-managed Diabetes Medication Therapy Adherence Clinic (DMTAC) in the Endocrine Clinic, in operation since 2006.

Objective: To evaluate the effectiveness of the pharmacist-managed DMTAC program in improving glycaemic control, lipid parameters and patients’ medication adherence.

Method: A retrospective study among patients enrolled in the DMTAC program was conducted between September 2007 and December 2008. Data was included from patients with a glycosylated haemoglobin (HbA1c) >8% and who had completed eight visits with the pharmacists. Medical records and DMTAC forms that provided patients’ demographics, medication regimens, adherence and laboratory parameters as well as pharmacists’ interventions were reviewed. HbA1c, fasting blood glucose (FBG), low-density lipoprotein cholesterol (LDL), triglycerides (TG) and high-density lipoprotein cholesterol (HDL) were evaluated. Documented data of patients’ adherence to medication regimen [Modified Morisky Medication Adherence Score (MMMAS); high adherence if score >8, medium adherence if score 6 to <8 and low adherence if score <6] was also evaluated.

Results: A total of 43 patients (53.5% females; 46.5% Malays, 44.2% Chinese and 9.3% Indians) were included in the analysis. A mean reduction in HbA1c of 1.73% (p<0.001), mean reduction in FBG of 2.65mmol/l (p=0.01) and mean reduction in LDL cholesterol of 0.38mmol/l (p=0.007) were achieved. The difference in TG and HDL cholesterol were not significant. Patients’ adherence to medication regimens improved significantly with an increase in the mean MMMAS score from 7.00 to 10.84 (p<0.001) after completion of the DMTAC program.

Conclusion: The pharmacist-managed DMTAC program resulted in significant improvements in HbA1c, glucose and LDL cholesterol levels as well as medication adherence in patients with diabetes.

Abstract 2108 | PDF Downloads 1007


1. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2003. Diabetes Care. 2004;27:1047-1053.

2. Mafauzy M. Diabetes Mellitus in Malaysia. Med J Malaysia. 2006;61(4):397-398.

3. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.

4. U.K. Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.

5. U.K. Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.

6. Cramer JA. A systemic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224.

7. Goudswaard AN, Stolk RP, Zuithoff NP, de Valk HW, Rutten GE. Long-term effects of self-management education for patients with Type 2 diabetes taking maximal oral hypoglycaemic therapy: a randomized trial in primary care. Diabet Med. 2004;21(5):491-496.

8. Lindenmeyer A., Hearnshaw H., Vermeire E., Van Royen P., Wens J., Biot Y. Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. J Clin Pharm Ther. 2006;31(5):409-419.

9. Renders CM, Valk GD, Griffin SJ, Wagner EH, Eijk Van JT, Assendelft WJ. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care. 2001;24:1821-1833.

10. Ramser KL, Sprabery LR, George CM, Hamann GL, Vallejo VA, Dorko G.S, Kuhl DA. Physician-pharmacist collaboration in the management of patients with diabetes resistant to usual care. Diabetes Spectrum. 2008;21(3):209-214.

11. Morisky DE., Ang A., Krousel-Wood M., Ward HJ. Predictive Validity of a Medication Adherence Measure for Hypertension Control. J Clin Hypertens (Greenwich). 2008;10(5):348-354.

12. Kiel PJ, McCord AD. Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005:39(11):1828-1832.

13. Leal S., Glover JJ, Herrier RN., Felix A. Improving quality care in diabetes through a comprehensive pharmacist-based disease management program. Diabetes Care. 2004;27:2983-2984.

14. Coast-Senior EA, Kroner BA, Kelley CL, Trilli ET. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636-640.

15. Anaya JP, Rivera JO, Lawson K, Garcia J, Luna J Jr, Ortiz M. Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm. 2008;65:1841-1845.

16. Clinical Practice Guidelines: Management of Type 2 Diabetes Mellitus (4th Edition). Ministry of Health Malaysia 2009 May.

17. Shillinger D, Grumbach K, Piette J, Wang F, Osmond D, Daher C, Palacios J, Sullivan GD, Bindman AD. Association of health literacy with diabetes outcomes. JAMA. 2002;288(4):475-482.

18. Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: A randomized pharmacist intervention. Ann Pharmacother. 2005;39(3):433-440.

19. WHO. Obesity: Preventing and managing the global epidemic. Report on a WHO Consultation on Obesity, Geneva, 3-5 June 1997. Geneva: World Health Organization; 1998.

20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.

21. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.

22. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.